Investor directory

Ambit Biosciences

Ambit Biosciences is a privately-held biopharmaceutical company that specializes in the discovery and development of small molecule kinase inhibitors aimed at treating cancer and inflammatory diseases. The company's lead compound, AC220, is a selective and orally bioavailable inhibitor of FMS-like tyrosine kinase-3 (FLT3), currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various therapeutic areas. In addition to AC220, Ambit's clinical pipeline features AC480, a pan-HER inhibitor, and AC430, an oral inhibitor of JAK2. Furthermore, the company has several preclinical candidates, including CEP-32496, a BRAF inhibitor that is licensed to Cephalon. Through its innovative approach, Ambit aims to enhance treatment outcomes for cancer patients.
http://www.ambitbio.com
https://crunchbase.com/organization/ambit-biosciences
https://linkedin.com/company/ambit-biosciences

Denise Trone

Director, Biostatistcs

1 past transactions

Afraxis

Series A in 2008
Afraxis, Inc. is a contract research organization based in San Diego, California, founded in 2007. The company specializes in preclinical efficacy evaluations, including in vivo and in vitro studies, neurotoxicity assessments, and structure-efficacy relationship-driven medicinal chemistry. Afraxis has developed enhanced spine profiling technology, which provides detailed insights into synaptic networks through high-resolution imaging and rapid morphometric analysis of individual neurons and synapses. Additionally, the company offers services in drug discovery and high-content analysis, encompassing live cell imaging and advanced statistical methods for data interpretation. Afraxis focuses on developing treatments for central nervous system disorders, including schizophrenia, Alzheimer's disease, Fragile X syndrome, and autism spectrum disorders, while also researching proprietary PAK inhibitors for these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.